Industry | 制造业 | ||||||||||||||||||||||||
Company Introduction | 首药控股(北京)股份有限公司成立于2016年4月19日,专注于具有自主知识产权的创新药的研发和生产,目前已获得国家1类创新药临床批件18个,其中1个新药申报上市、1个新药完成临床Ⅲ期、5个新药进入临床Ⅱ期、10个新药进入临床I期。让我们在“责、权、利”清晰而又扛得住的机制里,把首药控股锻造成为集研发、生产、销售于一体的国际化药企。 | ||||||||||||||||||||||||
Main Business | 从事小分子靶向创新药的研发 | ||||||||||||||||||||||||
Legal Representative | 李文军 | ||||||||||||||||||||||||
Top Executives |
|
||||||||||||||||||||||||
Top 5 Shareholder |
|
||||||||||||||||||||||||
Company Secretary | 张英利 | ||||||||||||||||||||||||
Solicitors | 北京市竞天公诚律师事务所 | ||||||||||||||||||||||||
Auditors | 天健会计师事务所(特殊普通合伙) | ||||||||||||||||||||||||
Tel No | 010-88857906 | ||||||||||||||||||||||||
Fax No | 010-88853760 | ||||||||||||||||||||||||
Website | www.shouyaoholding.com | ||||||||||||||||||||||||
shouyaoholding@163.com | |||||||||||||||||||||||||
Company Address |
|
||||||||||||||||||||||||
Listing Date | 23/03/2022 | ||||||||||||||||||||||||
Shares Capital |
|
||||||||||||||||||||||||
EPS(RMB)* | ¥ -1.250 | ||||||||||||||||||||||||
DPS(RMB)* | -- | ||||||||||||||||||||||||
NBV Per Share(RMB)* | ¥ 6.865 | ||||||||||||||||||||||||
Market Capitalization(RMB) | 1.893B |
Only Chinese content is avaliable | |
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
* | Unadjusted Data |
Information provided by: etnet | ||
Terms and Conditions |
Risk Disclosure: |
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
Disclaimer: |
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |